A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 63955
NMA SSA Reference Number: SSA/63955/MonH-2020-232699(v1)
Monash Health Reference: RES-20-0000-342A
Effective start/end date25/11/2024/11/25


  • treatment efficacy
  • clinical trial
  • treatment safety
  • endometrial cancer